Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review
Abstract
:1. Introduction
2. Systemic Sclerosis (SSc)
2.1. Glucocorticoids (GC)
2.2. Cyclophosphamide (CYC)
2.3. Mycophenolate Mofetil (MMF)
2.4. Azathioprine (AZA)
2.5. Rituximab (RTX)
2.6. Hematopoietic Stem Cell Transplantation (HSCT)
2.7. Lung Transplantation
2.8. Tyrosine Kinase Inhibitor
2.9. Pirfenidone
2.10. IL-6 Blockade
3. Idiopathic Inflammatory Myopathies (IIM)
3.1. Polymyositis (PM), Dermatomyositis (DM), Amyopathic Dermatomyositis
3.1.1. Glucocorticoids (GC)
3.1.2. Cyclophosphamide (CYC)
3.1.3. Mycophenolate Mofetil (MMF) and Azathioprine (AZA)
3.1.4. Calcineurin Inhibitors
3.1.5. Methotrexate (MTX)
3.2. Antisynthetase Syndrome (ASSD)
3.3. Others (Intravenous Immunoglobulins, Plasmapheresis, Lung Transplantation) in IIM and ASSD-ILD
4. Primary Sjogren Syndrome (pSS)
4.1. Glucocorticoids (GCs) and Conventional Immunosuppressive Agents
4.2. Rituximab (RTX)
4.3. IL-6 Blockade, Tocilizumab
5. Systemic Lupus Erythematosus (SLE)
6. Mixed Connective Tissue Disease (MCTD)
7. Undifferentiated Connective Tissue Disease (UCTD)
8. Acute Exacerbation (AE)
8.1. Pharmacological Treatment
8.2. Supportive Care
9. Non-Pharmacological Treatments
10. Ongoing Randomized Trials
11. Conclusions
12. Highlights
- The correct clinical and therapeutic management of CTDs-ILD needs a multidisciplinary approach including expert rheumatologist, pulmonologist, and thoracic radiologist;
- Treatment with conventional or biologic disease-modifying antirheumatic drug (DMARDs) is often based on expert-opinion and low-quality studies in CTD-ILD;
- Randomized controlled studies are available only for RTX, CYC, MMF, TCZ, and anti-fibrotics, mainly in SSc and sometimes without conclusive results;
- A possible role of antifibrotic treatment in CTDs-ILD has been supposed by some Authors; the INBUILD study demonstrated the efficacy of nintedanib in secondary form of ILD, including CTD;
- Further prospective studies are mandatory to investigate the efficacy and safety of the different treatment regimens in CTDs-ILD;
Author Contributions
Conflicts of Interest
References
- Castellino, F.V.; Varga, J. Interstitial lung disease in connective tissue diseases: Evolving concepts of pathogenesis and management. Arthritis Res. Ther. 2010, 12, 213. [Google Scholar] [CrossRef] [Green Version]
- Wallace, B.; Vummidi, D.; Khanna, D. Management of connective tissue diseases associated interstitial lung disease: A review of the published literature. Curr. Opin. Rheumatol. 2016, 28, 236–245. [Google Scholar] [CrossRef] [PubMed]
- Khanna, D.; Mittoo, S.; Aggarwal, R.; Proudman, S.M.; Dalbeth, N.; Matteson, E.L.; Brown, K.; Flaherty, K.; Wells, A.U.; Seibold, J.R.; et al. Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD)-Report from OMERACT CTD-ILD Working Group. J. Rheumatol. 2015, 42, 2168–2171. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ferri, C.; Manfredi, A.; Sebastiani, M.; Colaci, M.; Giuggioli, D.; Vacchi, C.; Della Casa, G.; Cerri, S.; Torricelli, P.; Luppi, F. Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: Our interdisciplinary rheumatology-pneumology experience, and review of the literature. Autoimmun. Rev. 2016, 15, 61–70. [Google Scholar] [CrossRef] [PubMed]
- Fischer, A.; Antoniou, K.M.; Brown, K.K.; Cadranel, J.; Corte, T.J.; du Bois, R.M.; Lee, J.S.; Leslie, K.O.; Lynch, D.A.; Matteson, E.L.; et al. “ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD”. An official European Respiratory Society/American Thoracic Society research statement: Interstitial pneumonia with autoimmune features. Eur. Respir. J. 2015, 46, 976–987. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vij, R.; Strek, M.E. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 2013, 143, 814–824. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Manfredi, A.; Sebastiani, M.; Cerri, S.; Cassone, G.; Bellini, P.; Della Casa, G.; Luppi, F.; Ferri, C. Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement. Clin. Rheumatol. 2017, 36, 1261–1268. [Google Scholar] [CrossRef] [PubMed]
- Travis, W.D.; Costabel, U. ATS/ERS committee on idiopathic interstitial pneumonias. An official American thoracic society/European respiratory society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013, 188, 733–748. [Google Scholar] [CrossRef]
- Tashkin, D.P.; Elashoff, R.; Clements, P.J.; Goldin, J.; Roth, M.D.; Furst, D.E.; Arriola, E.; Silver, R.; Strange, C.; Bolster, M.; et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 2006, 354, 2655–2666. [Google Scholar] [CrossRef] [Green Version]
- Tashkin, D.P.; Elashoff, R.; Clements, P.J.; Roth, M.D.; Furst, D.E.; Silver, R.M.; Goldin, J.; Arriola, E.; Strange, C.; Bolster, M.B.; et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am. J. Respir. Crit. Care Med. 2007, 176, 1026–1034. [Google Scholar] [CrossRef]
- Goldin, J.; Elashoff, R.; Kim, H.J.; Yan, X.; Lynch, D.; Strollo, D.; Roth, M.D.; Clements, P.; Furst, D.E.; Khanna, D.; et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: Findings from the scleroderma lung study. Chest 2009, 136, 1333–1340. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hoyles, R.K.; Ellis, R.W.; Wellsbury, J.; Roberts, C.; Desai, S.; Herrick, A.L.; McHugh, N.J.; Foley, N.M.; Pearson, S.B.; Emery, P.; et al. A multicenter, prospective, randomized, doubleblind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006, 54, 3962–3970. [Google Scholar] [CrossRef] [PubMed]
- Tashkin, D.P.; Roth, M.D.; Clements, P.J.; Furst, D.E.; Khanna, D.; Kleerup, E.C.; Goldin, J.; Arriola, E.; Volkmann, E.R.; Silver, R.; et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial. Lancet Respir. Med. 2016, 4, 708–719. [Google Scholar] [CrossRef]
- Volkmann, E.R.; Tashkin, D.P.; Li, N.; Roth, M.D.; Khanna, D.; Hoffmann-Vold, A.M.; Kim, G.; Goldin, J.; Clements, P.J.; Furst, D.E.; et al. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis–Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Arthritis Rheumatol. 2017, 69, 1451–1460. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nadashkevich, O.; Davis, P.; Fritzler, M.; Kovalenko, W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin. Rheumatol. 2006, 25, 205–212. [Google Scholar] [CrossRef]
- Daoussis, D.; Liossis, S.N.; Tsamandas, A.C.; Karampetsou, M.; Yiannopoulos, G.; Andonopoulos, A.P. Experience with rituximab in scleroderma: Results from a 1-year, proof-of-principle study. Rheumatology 2010, 49, 271–280. [Google Scholar] [CrossRef] [Green Version]
- Clinicaltrials.gov. Available online: https://clinicaltrials.gov/ct2/show/study/NCT01748084 (accessed on 7 December 2019).
- Van Laar, J.M.; Farge, D.; Sont, J.K.; Naraghi, K.; Marjanovic, Z.; Larghero, J.; Schuerwegh, A.J.; Marijt, E.W.; Matucci-Cerinic, M.; Voskuyl, A.E.; et al. Autologous hematopoietic stem cell transplantation vs. intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: A randomized clinical trial. JAMA 2014, 311, 2490–2498. [Google Scholar] [CrossRef]
- Burt, R.K.; Shah, S.J.; Dill, K.; Grant, T.; Gheorghiade, M.; Schroeder, J.; Craig, R.; Hirano, I.; Marshall, K.; Ruderman, E.; et al. Autologous non myeloablative haematopoietic stem cell transplantaion compared with pulse cyclophosphamide once per month for Systemic sclerosis (ASSIST): An open label randomized phase 2 trial. Lancet 2011, 378, 498–506. [Google Scholar] [CrossRef]
- Sullivan, K.M.; Goldmuntz, E.A.; Keyes-Elstein, L.; McSweeney, P.A.; Pinckney, A.; Welch, B.; Mayes, M.D.; Nash, R.A.; Crofford, L.J.; Khanna, D.; et al. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N. Engl. J. Med. 2018, 378, 35–47. [Google Scholar] [CrossRef]
- Distler, O.; Brown, K.K.; Distler, J.H.W.; Assassi, S.; Maher, T.M.; Cottin, V.; Varga, J.; Coeck, C.; Gahlemann, M.; Sauter, W.; et al. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS TM). Clin. Exp. Rheumatol. 2017, 35, 75–81. [Google Scholar]
- Khanna, D.; Saggar, R.; Mayes, M.D.; Abtin, F.; Clements, P.J.; Maranian, P.; Assassi, S.; Saggar, R.; Singh, R.R.; Furst, D.E. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 2011, 63, 3540–3546. [Google Scholar] [CrossRef] [PubMed]
- Fraticelli, P.; Gabrielli, B.; Pomponio, G.; Valentini, G.; Bosello, S.; Riboldi, P.; Gerosa, M.; Faggioli, P.; Giacomelli, R.; Del Papa, N.; et al. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: A phase II pilot study. Arthritis Res. Ther. 2014, 8, R144. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Martyanov, V.; Kim, G.J.; Hayes, W.; Du, S.; Ganguly, B.J.; Sy, O.; Lee, S.K.; Bogatkevich, G.S.; Schieven, G.L.; Schiopu, E.; et al. Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease. PLoS ONE 2017, 9, e0187580. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Khanna, D.; Albera, C.; Fischer, A.; Khalidi, N.; Raghu, G.; Chung, L.; Chen, D.; Schiopu, E.; Tagliaferri, M.; Seibold, J.R.; et al. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: The LOTUSS Trial. J. Rheumatol. 2016, 43, 1672–1679. [Google Scholar] [CrossRef] [Green Version]
- Clinicaltrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT03221257 (accessed on 7 December 2019).
- Khanna, D.; Denton, C.P.; Jahreis, A.; van Laar, J.M.; Frech, T.M.; Anderson, M.E.; Baron, M.; Chung, L.; Fierlbeck, G.; Lakshminarayanan, S.; et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): A phase 2, randomised, controlled trial. Lancet 2016, 387, 2630–2640. [Google Scholar] [CrossRef]
- Khanna, D.; Lin, C.J.F.; Kuwana, M.; Allanore, Y.; Batalov, A.; Butrimieneet, I.; Baron, M.; Chung, L.; Fierlbeck, G.; Lakshminarayanan, S.; et al. Efficacy and safety of tocilizumab for the treatment of systemic sclerosis: Results from a phase 3 randomized controlled trial. Presented at the American College of Rheumatology (ACR)/Association of Rheumatology Professionals (ARHP) Annual Meeting, Chicago, IL, USA, 19–24 October 2018. [Google Scholar]
- Allenbach, Y.; Guiguet, M.; Rigolet, A.; Marie, I.; Hachulla, E.; Drouot, L.; Jouen, F.; Jacquot, S.; Mariampillai, K.; Musset, L.; et al. Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti-Synthetase Auto-Antibodies: An Open-Label, Phase II Trial. PLoS ONE. 2015, 5, e0133702. [Google Scholar] [CrossRef]
- Clinical trial.gov. Available online: https://www.clinicaltrials.gov/ct2/show/NCT03215927 (accessed on 15 January 2020).
- Saunders, P.; Tsipouri, V.; Keir, G.J.; Ashby, D.; Flather, M.D.; Parfrey, H.; Babalis, D.; Renzoni, E.A.; Denton, C.P.; Wells, A.U.; et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): Study protocol for a randomised controlled trial. Trials 2017, 15, 275. [Google Scholar] [CrossRef] [Green Version]
- Flaherty, K.R.; Wells, A.U.; Cottin, V.; Devaraj, A.; Walsh, S.L.F.; Inoue, Y.; Richeldi, L.; Kolb, M.; Clerisme-Beaty, E.; Rosenstock, B.; et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N. Engl. J. Med. 2019, 31, 1718–1727. [Google Scholar] [CrossRef] [Green Version]
- Silver, K.C.; Silver, R.M. Management of Systemic-Sclerosis-Associated Interstitial Lung Disease. Rheum. Dis. Clin. N. Am. 2015, 41, 439–457. [Google Scholar] [CrossRef] [Green Version]
- Adler, S.; Huscher, D.; Siegert, E.; Allanore, Y.; Czirják, L.; DelGaldo, F.; Denton, C.P.; Distler, O.; Frerix, M.; Matucci-Cerinic, M.; et al. Systemic sclerosis associated interstitial lung disease-individualized immunosuppressive therapy and course of lung function: Results of the EUSTAR group. Arthritis Res. Ther. 2018, 30, 17. [Google Scholar] [CrossRef] [Green Version]
- Mango, R.L.; Matteson, E.L.; Crowson, C.S.; Ryu, J.H.; Makol, A. Assessing Mortality Models in Systemic Sclerosis-Related Interstitial Lung Disease. Lung 2018, 196, 409–416. [Google Scholar] [CrossRef] [PubMed]
- Goh, N.S.; Desai, S.R.; Veeraraghavan, S.; Hansell, D.M.; Copley, S.J.; Maher, T.M.; Corte, T.J.; Sander, C.R.; Ratoff, J.; Devaraj, A.; et al. Interstitial lung disease in systemic sclerosis: A simple staging system. Am. J. Respir. Crit. Care Med. 2008, 177, 1248–1254. [Google Scholar] [CrossRef] [PubMed]
- Volkmann, E.R.; Tashkin, D.P. Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies. Ann. Am. Thorac. Soc. 2016, 13, 2045–2056. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Steen, V.D.; Medsger, T.A., Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998, 41, 1613–1619. [Google Scholar] [CrossRef]
- Kowal-Bielecka, O.; Fransen, J.; Avouac, J.; Becker, M.; Kulak, A.; Allanore, Y.; Distler, O.; Clements, P.; Cutolo, M.; Czirjak, L.; et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann. Rheum. Dis. 2017, 76, 1327–1339. [Google Scholar] [CrossRef] [Green Version]
- Roth, M.D.; Tseng, C.H.; Clements, P.J.; Furst, D.E.; Tashkin, D.P.; Goldin, J.G.; Khanna, D.; Kleerup, E.C.; Li, N.; Elashoff, D.; et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum. 2011, 63, 2797–2808. [Google Scholar] [CrossRef]
- Becker, M.O.; Schohe, A.; Weinert, K.; Huscher, D.; Schneider, U.; Burmester, G.R.; Riemekasten, G. Responders to cyclophosphamide: Results of a single-centre analysis among systemic sclerosis patients. Ann. Rheum. Dis. 2012, 71, 2061–2062. [Google Scholar] [CrossRef]
- Akesson, A. Cyclophosphamide therapy for scleroderma. Curr. Opin. Rheumatol. 1998, 10, 579–583. [Google Scholar]
- Nihtyanova, S.I.; Brough, G.M.; Black, C.M.; Denton, C.P. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis: A retrospective analysis. Rheumatology 2007, 46, 442–445. [Google Scholar] [CrossRef] [Green Version]
- Gerbino, A.J.; Goss, C.H.; Molitor, J.A. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008, 133, 455–460. [Google Scholar] [CrossRef]
- Simeon-Aznar, C.P.; Fonollosa-Pl’a, V.; Tolosa-Vilella, C.; SelvaO’Callaghan, A.; Solans-Laqu’e, R.; Vilardell-Tarr’es, M. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin. Rheumatol. 2011, 30, 1393–1398. [Google Scholar] [CrossRef] [PubMed]
- Swigris, J.J.; Olson, A.L.; Fischer, A.; Lynch, D.A.; Cosgrove, G.P.; Frankel, S.K.; Meehan, R.T.; Brown, K.K. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease–related interstitial lung disease. Chest 2006, 130, 30–36. [Google Scholar] [CrossRef]
- Zamora, A.C.; Wolters, P.J.; Collard, H.R.; Connolly, M.K.; Elicker, B.M.; Webb, W.R.; King, T.E., Jr.; Golden, J.A. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir. Med. 2008, 102, 150–155. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Koutroumpas, A.; Ziogas, A.; Alexiou, I.; Barouta, G.; Sakkas, L.I. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin. Rheumatol. 2010, 29, 1167–1168. [Google Scholar] [CrossRef] [PubMed]
- Oldham, J.M.; Lee, C.; Valenzi, E.; Witt, L.J.; Adegunsoye, A.; Hsu, S.; Chen, L.; Chen, L.; Montner, S.; Chung, J.H.; et al. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respir. Med. 2016, 121, 117–122. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bérezné, A.; Ranque, B.; Valeyre, D.; Brauner, M.; Allanore, Y.; Launay, D.; Le Guern, V.; Kahn, J.E.; Couderc, L.J.; Constans, J.; et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: A retrospective multicenter open-label study. J. Rheumatol. 2008, 35, 1064–1072. [Google Scholar]
- Owen, C.; Ngian, G.S.; Elford, K.; Moore, O.; Stevens, W.; Nikpour, M.; Rabusa, C.; Proudman, S.; Roddy, J.; Zochling, J.; et al. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lungdisease: Results from the Australian Scleroderma Cohort Study. Clin. Exp. Rheumatol. 2016, 34, 170–176. [Google Scholar]
- Iudici, M.; Cuomo, G.; Vettori, S.; Bocchino, M.; Sanduzzi Zamparelli, A.; Cappabianca, S.; Valentini, G. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): Efficacy of maintenance immunosuppression in responders and non-responders. Semin. Arthritis Rheum. 2015, 44, 437–444. [Google Scholar] [CrossRef] [Green Version]
- Bosello, S.L.; De Luca, G.; Rucco, M.; Berardi, G.; Falcione, M.; Danza, F.M.; Pirronti, T.; Ferraccioli, G. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin. Arthritis Rheum. 2015, 44, 428–436. [Google Scholar] [CrossRef]
- Jordan, S.; Distler, J.H.; Maurer, B.; Huscher, D.; van Laar, J.M.; Allanore, Y.; Distler, O. Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann. Rheum. Dis. 2014, 74, 1188–1194. [Google Scholar] [CrossRef]
- Daoussis, D.; Melissaropoulos, K.; Sakellaropoulos, G.; Antonopoulos, I.; Markatseli, T.E.; Simopoulou, T.; Georgiou, P.; Andonopoulos, A.P.; Drosos, A.A.; Sakkas, L.; et al. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin. Arthritis Rheum. 2017, 46, 625–631. [Google Scholar] [CrossRef] [PubMed]
- Mohammed, A.G.A.; Alshihre, A.; Al-Homood, I.A. Rituximab treatment in patients with systemic sclerosis and interstitial lung disease. Ann. Thorac. Med. 2017, 12, 294–297. [Google Scholar] [PubMed]
- Giuggioli, D.; Lumetti, F.; Colaci, M.; Fallahi, P.; Antonelli, A.; Ferri, C. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun. Rev. 2015, 14, 1072–1078. [Google Scholar] [CrossRef] [PubMed]
- Sari, A.; Guven, D.; Armagan, B.; Erden, A.; Kalyoncu, U.; Karadag, O.; Apras Bilgen, S.; Ertenli, I.; Kiraz, S.; Akdogan, A. Rituximab Experience in Patients With Long-standing Systemic Sclerosis-Associated Interstitial Lung Disease: A Series of 14 Patients. J. Clin. Rheumatol. 2017, 23, 411–415. [Google Scholar] [CrossRef] [PubMed]
- Daoussis, D.; Liossis, S.N.; Tsamandas, A.C.; Kalogeropoulou, C.; Paliogianni, F.; Sirinian, C. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin. Exp. Rheumatol. 2012, 30, S17–S22. [Google Scholar]
- Eyraud, A.; Scouppe, L.; Barnetche, T.; Forcade, E.; Lazaro, E.; Duffau, P.; Richez, C.; Seneschal, J.; Truchetet, M.E. FHU ACRONIM. Efficacy and safety of autologous haematopoietic stem cell transplantation in systemic sclerosis: A systematic review of literature. Br. J. Dermatol. 2017, 178, 650–658. [Google Scholar]
- Bernstein, E.J.; Peterson, E.R.; Sell, J.L.; D’Ovidio, F.; Arcasoy, S.M.; Bathon, J.M.; Lederer, D.J. Survival of adults with systemic sclerosis following lung transplantation: A nationwide cohort study. Arthritis Rheumatol. 2015, 67, 1314–1322. [Google Scholar] [CrossRef] [Green Version]
- Khan, I.Y.; Singer, L.G.; de Perrot, M.; Granton, J.T.; Keshavjee, S.; Chau, C.; Kron, A.; Johnson, S.R. Survival after lung transplantation in systemic sclerosis: A systematic review. Respir. Med. 2013, 107, 2081–2087. [Google Scholar] [CrossRef] [Green Version]
- Sottile, P.D.; Iturbe, D.; Katsumoto, T.R.; Connolly, M.K.; Collard, H.R.; Leard, L.A.; Hays, S.; Golden, J.A.; Hoopes, C.; Kukreja, J.; et al. Outcomes in systemic sclerosis-related lung disease after lung transplantation. Transplantation 2013, 95, 975–980. [Google Scholar] [CrossRef] [Green Version]
- Crespo, M.M.; Bermudez, C.A.; Dew, M.A.; Johnson, B.A.; George, M.P.; Bhama, J. Lung transplantation in patients with scleroderma compared with pulmonary fibrosis: Short and long-term outcomes in a single institution. Ann. Am. Thorac. Soc. 2016, 13, 784–792. [Google Scholar] [CrossRef]
- Miele, C.H.; Schwab, K.; Saggar, R.; Duffy, E.; Elashoff, D.; Tseng, C.H. Lung transplant outcomes in systemic sclerosis with significant esophageal dysfunction: A comprehensive single center experience. Ann. Am. Thorac. Soc. 2016, 13, 793–802. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shitrit, D.; Amital, A.; Peled, N.; Raviv, Y.; Medalion, B.; Saute, M.; Kramer, M.R. Lung transplantation in patients with scleroderma: Case series, review of the literature, and criteria for transplantation. Clin. Transplant. 2009, 23, 178–183. [Google Scholar] [CrossRef] [PubMed]
- Schachna, L.; Medsger, T.A., Jr.; Dauber, J.H.; Wigley, F.M.; Braunstein, N.A.; White, B.; Steen, V.D.; Conte, J.V.; Yang, S.C.; McCurry, K.R.; et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum. 2006, 54, 3954–3961. [Google Scholar] [CrossRef] [PubMed]
- Fernández-Codina, A.; Berastegui, C.; Pinal-Fernández, I.; Silveira, M.G.; López-Meseguer, M.; Monforte, V.; Guillén-Del Castillo, A.; Simeón-Aznar, C.P.; Fonollosa-Plà, V.; Solé, J.; et al. Lung transplantation in systemic sclerosis: A single center cohort study. Jt. Bone Spine 2018, 85, 79–84. [Google Scholar] [CrossRef]
- Pradère, P.; Tudorache, I.; Magnusson, J.; Savale, L.; Brugiere, O.; Douvry, B.; Reynaud-Gaubert, M.; Claustre, J.; Borgne, A.L.; Holm, A.M.; et al. Lung transplantation for scleroderma lung disease: An international, multicenter, observational cohort study. J. Heart Lung Transplant. 2018, 37, 903–911. [Google Scholar] [CrossRef]
- Fisichella, P.M.; Reder, N.P.; Gagermeier, J.; Kovacs, E.J. Usefulness of pH monitoring in predicting the survival status of patients with scleroderma awaiting lung transplantation. J. Surg. Res. 2014, 189, 232–237. [Google Scholar] [CrossRef] [Green Version]
- Wollin, L.; Maillet, I.; Quesniaux, V.; Holweg, A.; Ryffel, B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J. Pharmacol. Exp. Ther. 2014, 349, 209–220. [Google Scholar] [CrossRef] [Green Version]
- Distler, O.; Highland, K.B.; Gahlemann, M.; Azuma, A.; Fischer, A.; Mayes, M.D.; Raghu, G.; Sauter, W.; Girard, M.; Alves, M.; et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N. Engl. J. Med. 2019, 380, 2518–2528. [Google Scholar] [CrossRef]
- Miura, Y.; Saito, T.; Fujita, K.; Tsunoda, Y.; Tanaka, T.; Takoi, H.; Yatagai, Y.; Rin, S.; Sekine, A.; Hayashihara, K.; et al. Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease. Sarcoidosis Vasc. Diffuse Lung Dis. 2014, 20, 235–238. [Google Scholar]
- Udwadia, Z.F.; Mullerpattan, J.B.; Balakrishnan, C.; Richeldi, L. Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. Lung India. 2015, 32, 50–52. [Google Scholar]
- Torres, C.; Belmonte, R.; Carmona, L.; Cabello, A.; Carreira, P.E. Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 2006, 39, 205–215. [Google Scholar] [CrossRef]
- Marie, I.; Hatron, P.Y.; Dominique, S.; Cherin, P.; Mouthon, L.; Menard, J.F. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: A series of 107 patients. Arthritis Rheum. 2011, 63, 3439–3447. [Google Scholar] [CrossRef]
- Morisset, J.; Johnson, C.; Rich, E.; Collard, H.R.; Lee, J.S. Management of Myositis-Related Interstitial Lung Disease. Chest 2016, 150, 1118–1128. [Google Scholar] [CrossRef] [PubMed]
- Solomon, J.; Swigris, J.J.; Brown, K.K. Myositis-related interstitial lung diseaseand antisynthetase syndrome. J. Bras. Pneumol. 2011, 37, 100–109. [Google Scholar] [CrossRef] [PubMed]
- Danko, K.; Ponyi, A.; Constantin, T.; Borgulya, G.; Szegedi, G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: A longitudinal study of 162 cases. Medicine 2004, 83, 35–42. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fujisawa, T.; Hozumi, H.; Kono, M.; Enomoto, N.; Hashimoto, D.; Nakamura, Y.; Inui, N.; Yokomura, K.; Koshimizu, N.; Toyoshima, M.; et al. Prognostic factors for myositis-associated interstitial lung disease. PLoS ONE 2014, 9, e98824. [Google Scholar] [CrossRef]
- Sharma, N.; Putman, M.S.; Vij, R.; Strek, M.E.; Dua, A. Myositis-associated Interstitial Lung Disease: Predictors of Failure of Conventional Treatment and Response to Tacrolimus in a US Cohort. J. Rheumatol. 2017, 44, 1612–1618. [Google Scholar] [CrossRef]
- Yoshifuji, H.; Fujii, T.; Kobayashi, S.; Imura, Y.; Fujita, Y.; Kawabata, D.; Usui, T.; Tanaka, M.; Nagai, S.; Umehara, H.; et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006, 39, 233–241. [Google Scholar] [CrossRef]
- Gono, T.; Kawaguchi, Y.; Satoh, T.; Kuwana, M.; Katsumata, Y.; Takagi, K.; Masuda, I.; Tochimoto, A.; Baba, S.; Okamoto, Y.; et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology 2010, 49, 1713–1719. [Google Scholar] [CrossRef] [Green Version]
- Hozumi, H.; Fujisawa, T.; Nakashima, R.; Johkoh, T.; Sumikawa, H.; Murakami, A.; Enomoto, N.; Inui, N.; Imura, Y.; Mimori, T.; et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir. Med. 2016, 121, 91–99. [Google Scholar] [CrossRef] [Green Version]
- Frazier, A.R.; Miller, R.D. Interstitial pneumonitis in association with polymyositis and dermatomyositis. Chest 1974, 65, 403–407. [Google Scholar] [CrossRef] [PubMed]
- Takada, T.; Suzuki, E.; Nakano, M.; Kagamu, H.; Tsukada, H.; Hasegawa, T.; Satoh, M.; Haraguchi, M.; Ebe, T.; Arakawa, M. Clinical features of polymyositis/dermatomyositis with steroid-resistant interstitial lung disease. Intern. Med. 1998, 37, 669–673. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ge, Y.; Peng, Q.; Zhang, S.; Zhou, H.; Lu, X.; Wang, G. Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: A systematic review. Clin. Rheumatol. 2015, 34, 99–105. [Google Scholar] [CrossRef] [PubMed]
- Meyer, O.; Hayem, G.; Palazzo, E.; Crestani, B.; Debray, M.P.; Ballard, M. Interstitial lung disease due to polymyositis or dermatomyositis: Effect of a 6-month course of i.v. pulse cyclophosphamide. Clin. Exp. Rheumatol. 2005, 23, 724. [Google Scholar] [PubMed]
- Schnabel, A.; Reuter, M.; Biederer, J.; Richter, C.; Gross, W.L. Interstitial lung disease in polymyositis and dermatomyositis: Clinical course and response to treatment. Semin. Arthritis Rheum. 2003, 32, 273–284. [Google Scholar] [CrossRef]
- Mira-Avendano, I.C.; Parambil, J.G.; Yadav, R.; Arrossi, V.; Xu, M.; Chapman, J.T.; Culver, D.A. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir. Med. 2013, 107, 890–896. [Google Scholar] [CrossRef] [Green Version]
- Yamasaki, Y.; Yamada, H.; Yamasaki, M.; Ohkubo, M.; Azuma, K.; Matsuoka, S.; Kurihara, Y.; Osada, H.; Satoh, M.; Ozaki, S. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology 2007, 46, 124–130. [Google Scholar] [CrossRef] [Green Version]
- Fischer, A.; Brown, K.K.; Du Bois, R.M.; Frankel, S.K.; Cosgrove, G.P.; Fernandez-Perez, E.R.; Huie, T.J.; Krishnamoorthy, M.; Meehan, R.T.; Olson, A.L.; et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J. Rheumatol. 2013, 40, 640–646. [Google Scholar] [CrossRef]
- Morganroth, P.A.; Kreider, M.E.; Werth, V.P. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res. 2010, 62, 1496–1501. [Google Scholar] [CrossRef] [Green Version]
- Cottin, V.; Thivolet-Bejui, F.; Reynaud-Gaubert, M.; Cadranel, P.; Delaval, P.J.; Ternamian, J.F.; Cordier, J.F. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur. Respir. J. 2003, 22, 245–250. [Google Scholar] [CrossRef] [Green Version]
- Douglas, W.W.; Tazelaar, H.D.; Hartman, T.E.; Hartman, R.P.; Decker, P.A.; Schroeder, D.R. Polymyositis-dermatomyositis associated interstitial lung disease. Am. J. Respir. Crit Care Med. 2001, 164, 1182–1185. [Google Scholar] [CrossRef] [PubMed]
- Mok, C.C.; To, C.H.; Szeto, M.L. Successful treatment of dermatomyositis related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine. Scand. J. Rheumatol. 2003, 32, 181–183. [Google Scholar] [CrossRef] [PubMed]
- Huapaya, J.A.; Silhan, L.; Pinal-Fernandez, I.; Casal-Dominguez, M.; Johnson, C.; Albayda, J.; Paik, J.J.; Sanyal, A.; Mammen, A.L.; Christopher-Stine, L.; et al. Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease. Chest 2019, 156, 896–906. [Google Scholar] [CrossRef] [PubMed]
- Nagasaka, K.; Harigai, M.; Tateishi, M.; Hara, M.; Yoshizawa, Y.; Koike, T.; Miyasaka, N. Efficacy of combination treatment with cyclosporin A and corticosteroids for acute interstitial pneumonitis associated with dermatomyositis. Mod. Rheumatol. 2003, 13, 231–238. [Google Scholar] [CrossRef]
- Kurita, T.; Yasuda, S.; Amengual, O.; Atsumi, T. The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis. Lupus 2015, 24, 3–9. [Google Scholar] [CrossRef]
- Kotani, T.; Takeuchi, T.; Makino, S.; Hata, K.; Yoshida, S.; Nagai, K.; Wakura, D.; Shoda, T.; Hanafusa, T. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin. Rheumatol. 2011, 30, 1021–1028. [Google Scholar] [CrossRef]
- Takada, K.; Nagasaka, K.; Miyasaka, N. Polymyositis/dermatomyositis and interstitial lung disease: A new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005, 38, 383–392. [Google Scholar] [CrossRef]
- Shimojima, Y.; Ishii, W.; Matsuda, M.; Kishida, D.; Ikeda, S.I. Effective Use of Calcineurin Inhibitor in Combination Therapy for Interstitial Lung Disease in Patients with Dermatomyositis and Polymyositis. J. Clin. Rheumatol. 2017, 23, 87–93. [Google Scholar] [CrossRef]
- Connors, G.R.; Christopher-Stine, L.; Oddis, C.V.; Danoff, S.K. Interstitial lung disease associated with the idiopathic inflammatory myopathies: What progress has been made in the past 35 years? Chest 2010, 138, 1464–1474. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kiely, P.D.; Chua, F. Interstitial lung disease in inflammatory myopathies: Clinical phenotypes and prognosis. Curr. Rheumatol. Rep. 2013, 15, 359. [Google Scholar] [CrossRef] [PubMed]
- Mimori, T.; Nakashima, R.; Hosono, Y. Interstitial lung disease in myositis: Clinical subsets, biomarkers, and treatment. Curr. Rheumatol. Rep. 2012, 14, 264–274. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oddis, C.V.; Sciurba, F.C.; Elmagd, K.A.; Starzl, T.E. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999, 353, 1762–1763. [Google Scholar] [CrossRef] [Green Version]
- Wilkes, M.R.; Sereika, S.M.; Fertig, N.; Lucas, M.R.; Oddis, C.V. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005, 52, 2439–2446. [Google Scholar] [CrossRef] [PubMed]
- Labirua-Iturburu, A.; Selva-O’Callaghan, A.; Martínez-Gómez, X.; Trallero-Araguás, E.; Labrador-Horrillo, M.; Vilardell-Tarrés, M. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. Clin. Exp. Rheumatol. 2013, 31, 436–439. [Google Scholar] [PubMed]
- Cavagna, L.; Caporali, R.; Abdi-Ali, L.; Dore, R.; Meloni, F.; Montecucco, C. Cyclosporine in anti-Jo1-positive patients with corticosteroid refractory interstitial lung disease. J. Rheumatol. 2013, 40, 484–492. [Google Scholar] [CrossRef] [PubMed]
- Kurita, T.; Yasuda, S.; Oba, K.; Odani, T.; Kono, M.; Otomo, K. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology 2015, 54, 39–44. [Google Scholar] [CrossRef] [Green Version]
- Sauty, A.; Rochat, T.; Schoch, O.D.; Hamacher, J.; Kurt, A.M.; Dayer, J.M.; Nicod, L.P. Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies. Eur. Respir. J. 1997, 10, 2907–2912. [Google Scholar] [CrossRef] [Green Version]
- Koreeda, Y.; Higashimoto, I.; Yamamoto, M.; Takahashi, M.; Kaji, K.; Fujimoto, M.; Kuwana, M.; Fukuda, Y. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern. Med. 2010, 49, 361–369. [Google Scholar] [CrossRef] [Green Version]
- Tellus, M.M.; Buchanan, R.R. Effective treatment of anti Jo-1 antibody-positive polymyositis with cyclosporine. Br. J. Rheumatol. 1995, 34, 1187–1188. [Google Scholar] [CrossRef]
- Rigby, A.L.; Plit, M.; Glanville, A.R. Tacrolimus rescue therapy for severe respiratory failure in the anti-synthetase syndrome. Respirol. Case Rep. 2014, 2, 70–72. [Google Scholar] [CrossRef]
- Ingegnoli, F.; Lubatti, C.; Ingegnoli, A.; Boracchi, P.; Zeni, S.; Meroni, P.L. Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients: A single centre study and review of the literature. Autoimmun. Rev. 2012, 11, 335–340. [Google Scholar] [CrossRef] [PubMed]
- Chen, I.J.; Jan Wu, Y.J.; Lin, C.W.; Fan, K.W.; Luo, S.F.; Ho, H.H. Interstitial lung disease in polymyositis and dermatomyositis. Clin. Rheumatol. 2009, 28, 639–646. [Google Scholar] [CrossRef] [PubMed]
- Hozumi, H.; Fujisawa, T.; Nakashima, R.; Yasui, H.; Suzuki, Y.; Kono, M.; Karayama, M.; Furuhashi, K.; Enomoto, N.; Inui, N.; et al. Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis. J. Rheumatol. 2019, 46, 509–517. [Google Scholar] [CrossRef] [PubMed]
- Vandenbroucke, E.; Grutters, J.C.; Altenburg, J.; Boersma, W.G.; ter Borg, E.J.; van den Bosch, J.M. Rituximab in life threatening antisynthetase syndrome. Rheumatol. Int. 2009, 29, 1499–1502. [Google Scholar] [CrossRef] [PubMed]
- Sharp, C.; McCabe, M.; Dodds, N.; Edey, A.; Mayers, L.; Adamali, H.; Millar, A.B.; Gunawardena, H. Rituximab in autoimmune connective tissue disease-associated interstitial lung disease. Rheumatology 2016, 55, 1318–1324. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marie, I.; Dominique, S.; Janvresse, A.; Levesque, H.; Menard, J.F. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir. Med. 2012, 106, 581–587. [Google Scholar] [CrossRef] [Green Version]
- Unger, L.; Kampf, S.; Luthke, K.; Aringer, M. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: Differential effects in a real-life population. Rheumatology 2014, 53, 1630–1638. [Google Scholar] [CrossRef] [Green Version]
- Keir, G.J.; Maher, T.M.; Ming, D.; Abdullah, R.; de Lauretis, A.; Wickremasinghe, M.; Nicholson, A.G.; Hansell, D.M.; Wells, A.U.; Renzoni, E.A. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 2014, 19, 353–359. [Google Scholar] [CrossRef]
- Sem, M.; Molberg, O.; Lund, M.B.; Gran, J.T. Rituximab treatment of the antisynthetase syndrome: A retrospective case series. Rheumatology 2009, 48, 968–971. [Google Scholar] [CrossRef] [Green Version]
- Ball, E.M.; Savage, E.M.; Pendleton, A. Refractory anti-synthetase syndrome treated with rituximab. Rheumatology 2010, 1013. [Google Scholar] [CrossRef] [Green Version]
- Andersson, H.; Sem, M.; Lund, M.B.; Aaløkken, T.M.; Günther, A.; Walle-Hansen, R.; Garen, T.; Molberg, Ø. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology 2015, 54, 1420–1428. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Diot, E.; Carmier, D.; Marquette, D.; Marchand-Adam, S.; Diot, P.; Lesire, V. IV immunoglobulin might be considered as a first-line treatment of severe interstitial lung disease associated with polymyositis. Chest 2011, 140, 562–563. [Google Scholar] [CrossRef]
- Bakewell, C.J.; Raghu, G. Polymyositis associated with severe interstitial lung disease: Remission after three doses of IV immunoglobulin. Chest 2011, 139, 441–443. [Google Scholar] [CrossRef] [PubMed]
- Suzuki, Y.; Hayakawa, H.; Miwa, S.; Shirai, M.; Fujii, M.; Gemma, H. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 2009, 187, 201–206. [Google Scholar] [CrossRef] [PubMed]
- Omotoso, B.A.; Ogden, M.I.; Balogun, R.A. Therapeutic plasma exchange in antisynthetase syndrome with severe interstitial lung disease. J. Clin. Apher. 2015, 30, 375–379. [Google Scholar] [CrossRef] [PubMed]
- Bozkirli, D.E.; Kozanoglu, I.; Bozkirli, E.; Yucel, E. Antisynthetase syndrome with refractory lung involvement and myositis successfully treated with double filtration plasmapheresis. J. Clin. Apher. 2013, 28, 422–425. [Google Scholar] [CrossRef]
- Kim, J.; Kim, Y.W.; Lee, S.M.; Kim, Y.S.; Kim, Y.T.; Song, Y.W. Successful lung transplantation in a patient with dermatomyositis and acute form of interstitial pneumonitis. Clin. Exp. Rheumatol. 2009, 27, 168–169. [Google Scholar]
- Shoji, T.; Bando, T.; Fujinaga, T.; Okubo, K.; Yukawa, N.; Mimori, T.; Suda, T.; Chida, K. Living-donor lobar lung transplantation for interstitial pneumonia associated with dermatomyositis. Gen. Thorac. Cardiovasc. Surg. 2010, 23, e10–e11. [Google Scholar] [CrossRef]
- Ameye, H.; Ruttens, D.; Benveniste, O.; Verleden, G.M.; Wuyts, W.A. Is lung transplantation a valuable therapeutic option for patients with pulmonary polymyositis? Experiences from the Leuven transplant cohort. Transplant. Proc. 2014, 46, 3147–3153. [Google Scholar] [CrossRef]
- Sem, M.; Lund, M.B.; Molberg, O. Long-term outcome of lung transplantation in a patient with the anti-synthetase syndrome. Scand. J. Rheumatol. 2011, 40, 327–328. [Google Scholar] [CrossRef]
- Courtwright, A.M.; El-Chemaly, S.; Dellaripa, P.F.; Goldberg, H.J. Survival and outcomes after lung transplantation for non-scleroderma connective tissue-related interstitial lung disease. J. Heart Lung Transplant. 2017, 36, 763–769. [Google Scholar] [CrossRef] [PubMed]
- Roca, F.; Dominique, S.; Schmidt, J.; Smail, A.; Duhaut, P.; Lévesque, H.; Marie, I. Interstitial lung disease in primary Sjögren’s syndrome. Autoimmun. Rev. 2017, 16, 48–54. [Google Scholar] [CrossRef]
- Robles-Perez, A.; Molina-Molina, M. Treatment Considerations of Lung Involvement in Rheumatologic Disease. Respiration 2015, 90, 265–274. [Google Scholar] [CrossRef] [PubMed]
- Ramos-Casals, M.; Brito-Zerón, P.; Sisó-Almirall, A.; Bosch, X.; Tzioufas, A.G. Topical and systemic medications for the treatment of primary Sjögren’s syndrome. Nat. Rev. Rheumatol. 2012, 1, 399–411. [Google Scholar] [CrossRef] [PubMed]
- Ramos-Casals, M.; Solans, R.; Rosas, J.; Camps, M.T.; Gil, A.; Del Pino-Montes, J.; Calvo-Alen, J.; Jiménez-Alonso, J.; Micó, M.L.; Beltrán, J.; et al. Primary Sjogren syndrome in Spain: Clinical and immunologic expression in 1010 patients. Medicine 2008, 87, 210–219. [Google Scholar] [CrossRef]
- Parambil, J.G.; Myers, J.L.; Lindell, R.M.; Matteson, E.L.; Ryu, J.H. Interstitial lung disease in primary Sjögren syndrome. Chest 2006, 130, 1489–1495. [Google Scholar] [CrossRef]
- Saraux, A.; Pers, J.O.; Devauchelle-Pensec, V. Treatment of primary Sjögren syndrome. Nat. Rev. Rheumatol. 2016, 12, 456–471. [Google Scholar] [CrossRef]
- Both, T.; Dalm, V.A.; van Hagen, P.M.; van Daele, P.L. Reviewing primary Sjögren’s syndrome: Beyond the dryness-From pathophysiology to diagnosis and treatment. Int. J. Med. Sci. 2017, 14, 191–200. [Google Scholar] [CrossRef] [Green Version]
- Gottenberg, J.E.; Cinquetti, G.; Larroche, C.; Combe, B.; Hachulla, E.; Meyer, O.; Pertuiset, E.; Kaplanski, G.; Feuillet, S.; Leone, J.; et al. Club Rhumatismes et Inflammations and the French Society of Rheumatology. Efficacy of rituximab in systemic manifestations of primary Sjogren’s syndrome: Results in 78 patients of the AutoImmune and Rituximab registry. Ann. Rheum. Dis. 2013, 72, 1026–1031. [Google Scholar] [CrossRef]
- Swartz, M.A.; Vivino, F.B. Dramatic reversal of lymphocytic interstitial pneumonitis in Sjögren’s syndrome with rituximab. J. Clin. Rheumatol. 2011, 17, 454. [Google Scholar] [CrossRef]
- Seror, R.; Sordet, C.; Guillevin, L.; Hachulla, E.; Masson, C.; Ittah, M.; Candon, S.; Le Guern, V.; Aouba, A.; Sibilia, J.; et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome. Ann. Rheum. Dis. 2007, 66, 351–357. [Google Scholar] [CrossRef]
- Justet, A.; Ottaviani, S.; Dieudé, P.; Taillé, C. Tocilizumab for refractory organising pneumonia associated with Sjögren’s disease. BMJ Case Rep. 2015, 14. [Google Scholar] [CrossRef]
- Weinrib, L.; Sharma, O.P.; Quismorio, F.P., Jr. A long-term study of interstitial lung disease in systemic lupus erythematosus. Semin. Arthritis Rheum. 1990, 20, 48–56. [Google Scholar] [CrossRef]
- Muangchan, C.; van Vollenhoven, R.F.; Bernatsky, S.R.; Smith, C.D.; Hudson, M.; Inanç, M.; Rothfield, N.F.; Nash, P.T.; Furie, R.A.; Senécal, J.L.; et al. Treatment Algorithms in Systemic Lupus Erythematosus. Arthritis Care Res. (Hoboken) 2015, 67, 1237–1245. [Google Scholar] [CrossRef]
- Mittoo, S.; Fell, C.D. Pulmonary manifestations of systemic lupus erythematosus. Semin. Respir. Crit. Care Med. 2014, 35, 249–254. [Google Scholar]
- Yang, B.B.; Man, X.Y.; Zheng, M. Pirfenidone combined with corticosteroids in a patient with systemic lupus erythematosus-associated interstitial lung disease. J. Eur. Acad. Dermatol. Venereol. 2017, 31, e388–e389. [Google Scholar] [CrossRef]
- Reiseter, S.; Gunnarsson, R.; Corander, J.; Haydon, J.; Lund, M.B.; Aaløkken, T.M.; Taraldsrud, E.; Hetlevik, S.O.; Molberg, Ø. Disease evolution in mixed connective tissue disease: Results from a long-term nationwide prospective cohort study. Arthritis Res. Ther. 2017, 21, 284. [Google Scholar] [CrossRef] [Green Version]
- Koo, S.M.; Uh, S.T. Treatment of connective tissue disease-associated interstitial lung disease: The pulmonologist’s point of view. Korean J. Intern. Med. 2017, 32, 600–610. [Google Scholar] [CrossRef]
- Graney, B.A.; Fischer, A. Advocating for early interstitial lung disease detection in mixed connective tissue disease. Rheumatology 2018, 1, 204–205. [Google Scholar] [CrossRef] [Green Version]
- Burdt, M.A.; Hoffman, R.W.; Deutscher, S.L.; Wang, G.S.; Johnson, J.C.; Sharp, G.C. Long-term outcome in mixed connective tissue disease: Longitudinal clinical and serologic findings. Arthritis Rheum. 1999, 42, 899–909. [Google Scholar] [CrossRef]
- Bodolay, E.; Szekanecz, Z.; Dévényi, K.; Galuska, L.; Csípo, I.; Vègh, J.; Garai, I.; Szegedi, G. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology 2005, 44, 656–661. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Manfredi, A.; Sebastiani, M.; Cerri, S.; Della Casa, G.; Giuggioli, D.; Vacchi, C.; Luppi, F.; Ferri, C. Unclassifiable interstitial lung disease or undifferentiated connective tissue disease? A challenging differential diagnosis Ann. Rheum. Dis. 2015, 74, 591. [Google Scholar]
- Maher, T.M.; Corte, T.J.; Fischer, A.; Kreuter, M.; Lederer, D.J.; Molina-Molina, M.; Axmann, J.; Kirchgaessler, K.U.; Samara, K.; Gilberg, F.; et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir. Med. 2019. [Google Scholar] [CrossRef]
- Chartrand, S.; Swigris, J.J.; Stanchev, L.; Lee, J.S.; Brown, K.K.; Fischer, A. Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience. Respir. Med. 2016, 119, 150–154. [Google Scholar] [CrossRef] [Green Version]
- Leuschner, G.; Behr, J. Acute Exacerbation in Interstitial Lung Disease. Front. Med. 2017, 23, 176. [Google Scholar] [CrossRef] [Green Version]
- Park, I.N.; Kim, D.S.; Shim, T.S.; Lim, C.M.; Lee, S.D.; Koh, Y.; Kim, W.S.; Kim, W.D.; Jang, S.J.; Colby, T.V. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest 2007, 132, 214–220. [Google Scholar] [CrossRef] [Green Version]
- Suda, T.; Kaida, Y.; Nakamura, Y.; Enomoto, N.; Fujisawa, T.; Imokawa, S.; Hashizume, H.; Naito, T.; Hashimoto, D.; Takehara, Y.; et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir. Med. 2009, 103, 846–853. [Google Scholar] [CrossRef] [Green Version]
- Tomiyama, F.; Watanabe, R.; Ishii, T.; Kamogawa, Y.; Fujita, Y.; Shirota, Y.; Sugimura, K.; Fujii, H.; Harigae, H. High Prevalence of Acute Exacerbation of Interstitial Lung Disease in Japanese Patients with Systemic Sclerosis. Tohoku J. Exp. Med. 2016, 239, 297–305. [Google Scholar] [CrossRef] [Green Version]
- Spagnolo, P.; Wuyts, W. Acute exacerbations of interstitial lung disease: Lessons from idiopathic pulmonary fibrosis. Curr. Opin. Pulm. Med. 2017, 23, 411–417. [Google Scholar] [CrossRef]
- Abe, M.; Tsushima, K.; Matsumura, T.; Ishiwata, T.; Ichimura, Y.; Ikari, J.; Terada, J.; Tada, Y.; Sakao, S.; Tanabe, N.; et al. Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: A nonrandomized prospective study. Drug Des. Dev. Ther. 2015, 5755–5762. [Google Scholar] [CrossRef] [Green Version]
- Ito, Y.; Tazaki, G.; Kondo, Y.; Takahashi, G.; Sakamaki, F. Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases. Respir. Med. Case Rep. 2019, 28, 317–320. [Google Scholar] [CrossRef] [PubMed]
- Tomioka, H.; Takata, H. Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis. Respirol. Case Rep. 2017, 12, e00215. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Richeldi, L.; du Bois, R.M.; Raghu, G.; Azuma, A.; Brown, K.K.; Costabel, U.; Cottin, V.; Flaherty, K.R.; Hansell, D.M.; Inoue, Y.; et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014, 370, 2071–2082. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Suissa, S.; Ernst, P. The INPULSIS trials of idiopathic pulmonary fibrosistreatment: Explaining further discrepancies on exacerbations. Eur. Respir. J. 2016, 47, 344–345. [Google Scholar] [CrossRef] [Green Version]
- Dowman, L.; Hill, C.J.; Holland, A.E. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst. Rev. 2014, 10, CD006322. [Google Scholar] [CrossRef]
- Rozenberg, D.; Sitzer, N.; Porter, S.; Weiss, A.; Colman, R.; Reid, D.W. Idiopathic Pulmonary Fibrosis: A review of disease, pharmacological and non-pharmacological strategies with a focus on symptoms, function, and health-related quality of life. J. Pain Symptom Manag. 2019. [Google Scholar] [CrossRef]
- Pakas, I.; Ioannidis, J.P.; Malagari, K.; Skopouli, F.N.; Moutsopoulos, H.M.; Vlachoyiannopoulos, P.G. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J. Rheumatol. 2002, 29, 298–304. [Google Scholar]
Systemic Sclerosis | ||||||||
---|---|---|---|---|---|---|---|---|
Trial | Year | Population | Phase | Follow-Up | Drug Investigated | Outcome | Results | |
SLS I [9] | 2006 | 145 SSc-ILD | Phase III | 12 Mo * | CYC | Oral CYC [72 pt] vs. PBO [73 pt] | I: FVC (%); II: TLC (%), PR-D, DLCO (%) | Oral CYC was associated with significant but modest improvement in FVC (%) compared with PBO and was associated with improvements in TLC (%), PR-D but not in DLCO (%). |
SLS I, FU extension [10] | 2007 | 145 SSc-ILD | Phase III | 24 Mo * | CYC | Oral CYC [72 pt] vs. PBO [73 pt] | I: FVC (%); II: TLC (%), PR-D, DLCO (%) | At a 24 month follow up, except for a sustained impact on dyspnea, the effects on FVC and TLC were no longer apparent. |
SLS I § [11] | 2009 | 98 SSc-ILD | Phase III | 12 Mo | CYC | Oral CYC [49 pt] vs. PBO [49 pt] | I: FVC (%), HRCT aspects (GGOs, FIB, Hcs scored on a scale of 0 to 4); II: TLC (%), DLCO (%) | At the end of FU, FIB was significantly worse in the PBO group than in the CYC group (p = 0.014) and these differences correlated significantly with FVC, TLC, and PR-D. No differences were noted in terms of GGOs and Hcs. |
FAST trial [12] | 2006 | 45 SSc-ILD | N.A. | 12 Mo | CYC-AZA | PDN + iv CYC + oral AZA as maintenance therapy [22 pt] or PBO [23pt]. | I: FVC (%), DLCO (%); II: HRCT (extent and pattern), PR-D | The improvement in terms of FVC (%) at the end of FU was modest but did not reach the statistical significance. Secondary outcome was not reached. |
SLS II [13] | 2016 | 126 SSc-ILD | Phase II | 24 Mo | MMF vs. CYC | MMF for 24 months [63 pt] vs. oral CYC for 12 months followed by PBO for 12 months [63 pt] | I: FVC (%); II: DLCO (%), PR-D, quantitative HRCT fibrosis scores. | Both MMF and CYC treatment resulted in significant improvements in FVC (%), DLCO (%), HRCT, PR-D. |
SLS I, II § [14] | 2017 | 122 SSc-ILD | N.A. | 24 Mo | MMF | SLS II-MMF (N = 61) and SLS I-PBO (N = 61) participants | I: FVC (%); II: DLCO (%), PR-D | MMF in comparison with PBO was associated with an improved course of FVC (%) (p < 0.0001), DLCO% (p < 0.001), and PR-D (p = 0.0112) after FU period. |
Nadashkevich et al. [15] | 2006 | 60 SSc° | N.A. | 18 Mo | CYC vs. AZA | Oral CYC [30 py] vs. oral AZA [30 pt]. PRD for the first 6 months. | I: FVC (%); DLCO (%), Chest X ray | FVC and DLCO did not change after treatment in the CYC-group, but statistically significantly worsened in the AZA-group. |
Daoussis et al. [16] | 2010 | 14 SSc-ILD | N.A. | 12 Mo | RTX | RTX [8 pt] vs. PBO [6 pt] | I: FVC (%), FEV1 (%), DLCO (%); II: HRCT score | There was a significant increase of FVC and DLCO in the RTX group compared with baseline (p = 0.0018 and p = 0.017). HRCT scores were identical at baseline and at 24 weeks in all patients in the RTX group, while in the control group, there was a modest nonsignificant increase. |
RECOVER trial [17] | 2013 | 22 SSc | Phase II/III | 12 Mo | RTX | RTX vs. PBO | II: Pulmonary functional tests | N.A. |
ASTIS trial [18] | 2014 | 156 SSc (n° SSc-ILD n.a.) | Phase II | 24 Mo | HSCT vs. CYC | HSCT [79 pt] vs. CYC [77 pt] | I: event-free survival. II: FVC (%), TLC (%); RV (%); DLCO (%) | HSCT therapy resulted in significant improvement in the FVC and total lung capacity (TLC) at a two-year follow-up |
ASSIST trial [19] | 2011 | 19 SSc-ILD | Phase II | 12 Mo | HSCT vs. CYC | HSCT [10 pt] vs. CYC [9 pt]. | FVC (%); DLCO (%); HRCT score | HSCT in comparison to CYC was more effective in improving FVC and decreasing diseased-lung volume. No effects on DLCO (%) was observed. |
SCOT trial [20] | 2018 | 73 Ssc-ILD | Phase II/III | 54 Mo | HSCT vs. CYC | HSCT [36 pt] vs. CYC [37 pt] | I: Global rank composite score including FVC (%) | HSCT achieved long-term benefits in patients with scleroderma, including improved event-free and overall survival Data regarding pulmonary function were not available. |
SENSCIS trial [21] | 2019 | 576 Ssc-ILD | Phase III | 12 Mo | Nintedanib | Nintedanib [288 pt] vs. PBO [288 pt] | I:FVC (mL) ^; II: FVC (%) ^, FVC (mL) $, DLCO (%)$ PR-D | Nintedanib significantly reduced the annual rate of decline in FVC at the end pf FU (p = 0.04), even if the relative reduction in FVC decline was similar in the two groups. Additionally, other pulmonary secondary outcomes were not reached. |
Khanna et al. [22] | 2011 | 20 SSc-ILD | Phase I/IIa | 12 Mo | Imatinib | Imatinib [20 pt] | I: FVC (%), DLCO (%), HRCT, PR-D | Imatinib led to trends toward improvement of 1.74% in the estimated FVC %, TLC % and in the DLCO % predicted over a 1-year period (p not significant). PR-D improved statistically, but the improvement was not clinically meaningful. |
Fraticelli et al. [23] | 2014 | 30 SSc-ILD | Phase II | 6 Mo * | Imatinib | Imatinib [30 pt] for 6 months | I: FVC (%), DLCO (%), HRCT, PR-D | Three patients died and one pt was lost to follow-up. Four pt had a good response, seven worsened and 15 had a stabilized lung disease. Overall, 19 pt had an improved or stabilized lung disease. After a 6-month follow-up, 12 (54.5%) of the 22 pt showed an improved or stabilized lung disease. |
Martyanov et al. [24] | 2017 | 31 SSc-ILD | Phase IIa | 18 Mo * | Dasatinib | Dasatinib for 6 months | II: PFT, PR-D, HRCT, Serum KL-6, SP-D, APRIL and adiponectin. | No significant changes in clinical assessments or serum biomarkers were seen at the end of FU. By quantitative HRCT, 65% of patients showed no progression of FIB, 39% showed no progression of total ILD. Improvers showed stability in FVC and DLCO, while both measures showed a decline in non-improvers (p = 0.1289 and p = 0.0195, respectively). |
LOTUSS trial [25] | 2016 | 63 SSc-ILD | Phase II | 5 We * | PRF | 2-week titration [32 pt] vs. 4-week titration [31pt] from 801 mg/d to 2403 mg/d, for 16 weeks. | EE: FVC (%), DLCO (%) | FVC (%) and DLCO (%) remained largely unchanged at the end of FU. |
SLS III [26] | 2017 | Recruiting (estimated 150 SSc-ILD) | Phase II | 18 Mo | MMF, PRF | MMF +PBO vs. MMF + PRF | I: FVC (%); II: DLCO (%), PR-D, HRCT | N.A. |
FaSScinate trial [27] | 2016 | 87 SSc | Phase II | 48 We | TCZ | TCZ [43 pt] vs. PBO [44 pt] | EE: FVC (mL and %) $, DLCO (%) $ | FVC showed a not significant decrease in TCZ group than PBO group at the end of FU and fewer pt in the TCZ group than in the PBO group had worsening of percent predicted FVC (p = 0·037). The change from baseline in DLCO (%) did not differ significantly between PBO and TCZ. |
FocuSSced trial [28] | 2018 | 212 SSc | Phase III | 48 We | TCZ | TCZ vs. PBO | II: FVC (%) $ | The cumulative distribution of change from baseline to week 48 in FVC (%) favored TCZ over PBO (p = 0.0015). The difference in mean change from baseline in FVC at week 48 was in favor of TCZ. Preservation of lung function with TCZ was shown by change from baseline in FVC over time. |
Dermatomyositis and Polymyositis | ||||||||
Allenbach et al. [29] | 2015 | 12 ASSD | Phase II | 12 Mo | RTX | RTX | II: Improvement of ILD (increase of 10% in FVC or 15% of DLCO %). | Improvement of FVC was observed in four patients, stabilization in 5 five and worsening in one. Only 1 pt with increased FVC (%) also showed an improvement of DLCO (%). In addition, one patient had an improvement of DLCO without significant change for FVC (data not shown). Finally, five patients had improving ILD measured by PFT. |
ATtackMy-ILD [30] | 2017 | Recruiting (estimated 20 ASSD-ILD) | Phase II | 6 Mo | ABA | ABA vs. PBO | I: FVC (%) $; II: time to progression free survival, PR-D, time to improvement in FVC% (≥10 points) | N.A. |
Connective tissue diseases | ||||||||
RECITAL [31] | 2013 | Recruiting (estimated 116 CTD-ILD) | Phase II/III | 48 We | RTX, CYC | RTX vs. CYC | I: FVC (mL); II: DLCO $ | N.A. |
INBUILD trial [32] | 2019 | 663 pt with progressive fibrosing ILD other than IPF (including CTDs) | Phase III | 52 We | Nintedanib | Nintedanib vs. PBO | I: FVC ^; II: absolute change from baseline in the total score on the King’s Brief Interstitial Lung Disease (K-BILD) questionnaire; time until the first acute exacerbation of ILD or death; | In patients with progressive fibrosing interstitial lung diseases, the annual rate of decline in the FVC was significantly lower among patients who received nintedanib than among those who received placebo. Diarrhea was a common adverse event. |
Systemic Sclerosis | Idiopathic Inflammatory Myopathy | Primary Sjogren Syndrome | Systemic Lupus Erythematosus | |
---|---|---|---|---|
Glucocorticoids | Prospective [171] Nested case control [38] Retrospective [34] | Prospective [89] Retrospective [98,100,101,112] | ||
Cyclophosphamide | Randomized clinical trial [9,10,11,12,13,15,40] Prospective [171] Retrospective [34,41,50,52] | Prospective [89] Retrospective [79,88,91,115] | ||
Mycophenolate Mofetil | Randomized clinical trial [13,14] Prospective [45] Retrospective [34,43,44,46,47,48,51] | Retrospective [79,92,93] | ||
Azathioprine | Randomized clinical trial [12,15] Retrospective [34,50] | Prospective [89] Retrospective [79] | ||
Rituximab | Randomized clinical trial [16,17] Prospective [57,59] Nested case control [54] Retrospective [53,55,56,58] | Randomized clinical trial [29] Retrospective [119,120,121,122,123,125] Case report [109,115] | Prospective [143] Retrospective [145] Case report [136] | |
Hematopoietic stem cells transplantation | Randomized clinical trial [18,19,20] | |||
Tyrosine kinase inhibitors | Randomized clinical trial [21,22,23,24,72] | |||
Pirfenidone | Randomized clinical trial [25,26] Prospective [73] Retrospective [74] | Case report [150] | ||
Calcineurin inhibitors | Prospective [106] Retrospective [81,97,98,99,100,102,107,108,109,110,112,114,115,117] | |||
Lung transplantation | Retrospective [61,63,64,65,66,67,68,69,70] | Retrospective [133,134,135] Case report [131,132] | ||
Plasma exchange | Case report [129,130] | |||
Intravenous Immunoglobulins | Retrospective [126,128] Case report [127] | |||
IL-6 inhibitors | Randomized clinical trial [27,28] | Case report [146] | ||
Methotrexate | Prospective [89] |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vacchi, C.; Sebastiani, M.; Cassone, G.; Cerri, S.; Della Casa, G.; Salvarani, C.; Manfredi, A. Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review. J. Clin. Med. 2020, 9, 407. https://doi.org/10.3390/jcm9020407
Vacchi C, Sebastiani M, Cassone G, Cerri S, Della Casa G, Salvarani C, Manfredi A. Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review. Journal of Clinical Medicine. 2020; 9(2):407. https://doi.org/10.3390/jcm9020407
Chicago/Turabian StyleVacchi, Caterina, Marco Sebastiani, Giulia Cassone, Stefania Cerri, Giovanni Della Casa, Carlo Salvarani, and Andreina Manfredi. 2020. "Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review" Journal of Clinical Medicine 9, no. 2: 407. https://doi.org/10.3390/jcm9020407
APA StyleVacchi, C., Sebastiani, M., Cassone, G., Cerri, S., Della Casa, G., Salvarani, C., & Manfredi, A. (2020). Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review. Journal of Clinical Medicine, 9(2), 407. https://doi.org/10.3390/jcm9020407